Prime Therapeutics’ Studies Examine Rheumatoid Arthritis Therapies and Total Cost

ST. PAUL, Minn., Oct. 17, 2017 /PRNewswire/ — Two new studies by pharmacy benefit manager Prime Therapeutics LLC (Prime) show commercially insured members with rheumatoid arthritis (RA) had 3.5 times higher total cost of care than members without RA. But optimizing conventional disease… https://www.prnewswire.com/news-releases/prime-therapeutics-studies-examine-rheumatoid-arthritis-therapies-and-total-cost-300536842.html